Artwork

Content provided by Donald Davis, PhD and Don Davis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Donald Davis, PhD and Don Davis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Dr. Alan Trounson - CEO of Cartherics Pty Ltd

40:29
 
Share
 

Manage episode 407351681 series 3563546
Content provided by Donald Davis, PhD and Don Davis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Donald Davis, PhD and Don Davis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of the Life Science Success Podcast, we're honored to have Dr. Alan Trounson, the CEO of Cartherics Pty Ltd, a company at the forefront of redefining cancer treatment through immunotherapy. Tune in as we discuss the future of cancer treatment, and much more!"

  • Dr. Alan Trounson, CEO of Cartherics Pty Ltd, has a rich background in reproductive sciences and stem cell research. He has been instrumental in the development of human IVF and embryonic stem cells, and has also led the California Institute for Regenerative Medicine with a $3 billion budget.

  • Cartherics aims to redefine cancer treatment through immunotherapy. The company is working on off-the-shelf CAR-T therapies that are designed to be low-cost and widely accessible, aiming to make cancer a manageable condition rather than a terminal one.

  • The company differentiates itself by focusing on overcoming immune inhibitors in solid tumors and recruiting the patient's own immune system for a more effective treatment. They are also involved in gene editing to extend the life of CAR-T cells and make them more effective.

  • Cartherics is in discussions with the FDA and plans to enter clinical trials by 2025. They are also collaborating with various international partners, including companies in Korea, China, Malaysia, and Australia, to bring in innovative ideas and technologies.

  • Dr. Trounson is enthusiastic about the science and the potential impact of their work. He believes that getting the science right is crucial for achieving the expected outcomes and is excited about the broader scientific developments in the field.

  continue reading

100 episodes

Artwork
iconShare
 
Manage episode 407351681 series 3563546
Content provided by Donald Davis, PhD and Don Davis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Donald Davis, PhD and Don Davis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of the Life Science Success Podcast, we're honored to have Dr. Alan Trounson, the CEO of Cartherics Pty Ltd, a company at the forefront of redefining cancer treatment through immunotherapy. Tune in as we discuss the future of cancer treatment, and much more!"

  • Dr. Alan Trounson, CEO of Cartherics Pty Ltd, has a rich background in reproductive sciences and stem cell research. He has been instrumental in the development of human IVF and embryonic stem cells, and has also led the California Institute for Regenerative Medicine with a $3 billion budget.

  • Cartherics aims to redefine cancer treatment through immunotherapy. The company is working on off-the-shelf CAR-T therapies that are designed to be low-cost and widely accessible, aiming to make cancer a manageable condition rather than a terminal one.

  • The company differentiates itself by focusing on overcoming immune inhibitors in solid tumors and recruiting the patient's own immune system for a more effective treatment. They are also involved in gene editing to extend the life of CAR-T cells and make them more effective.

  • Cartherics is in discussions with the FDA and plans to enter clinical trials by 2025. They are also collaborating with various international partners, including companies in Korea, China, Malaysia, and Australia, to bring in innovative ideas and technologies.

  • Dr. Trounson is enthusiastic about the science and the potential impact of their work. He believes that getting the science right is crucial for achieving the expected outcomes and is excited about the broader scientific developments in the field.

  continue reading

100 episodes

Semua episode

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide